Related Experiment Video

Updated: Nov 19, 2025

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

28.0K

Outcomes of Zoledronic Acid Use in Paediatric Conditions

Angelina Lim1,2,3, Peter J Simm1,3, Simon James4

  • 1Hormone Research, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.

Hormone Research in Paediatrics
|January 28, 2021
PubMed

Insights

Zoledronic acid (ZA) effectively improved bone density in pediatric patients with osteoporosis and stabilized avascular necrosis (AVN), showing good efficacy in this large cohort. This study highlights ZA

Area of Science:

  • Pediatric Endocrinology
  • Pediatric Rheumatology
  • Pediatric Orthopedics
  • Pharmacology

Background:

  • Limited data exists on zoledronic acid (ZA) use in pediatric patients for conditions beyond primary bone fragility.
  • Understanding ZA's efficacy and safety in diverse pediatric bone conditions is crucial for expanding its therapeutic applications.

Purpose of the Study:

  • To evaluate the outcomes of zoledronic acid (ZA) administration in a large pediatric cohort.
  • To assess ZA's efficacy in treating primary bone fragility, secondary osteoporosis, and other bone abnormalities like avascular necrosis (AVN).

Main Methods:

  • Retrospective review of pediatric patients (2002-2015) who received at least one dose of intravenous zoledronic acid (ZA).
  • Analysis of bone mineral density changes and clinical outcomes, including joint integrity and pain reduction for specific conditions.

Main Results:

  • Significant increases in bone mineral density Z-scores were observed in children treated for osteogenesis imperfecta, immobility-related conditions, and glucocorticoid-induced osteoporosis.
  • In patients with avascular necrosis (AVN), zoledronic acid (ZA) helped maintain joint integrity in a majority of cases and reduced pain.
  • Zoledronic acid (ZA) showed potential in reducing bone lesion size in patients with bone cysts.

Conclusions:

  • This study represents the largest reported cohort of zoledronic acid (ZA) outcomes in children.
  • Zoledronic acid (ZA) demonstrates a favorable efficacy profile, improving bone density in osteoporotic conditions and stabilizing avascular necrosis (AVN) with a low risk of joint collapse.
Abstract

Keywords:
Bone health in childrenBone mineral densityDuchenne muscular dystrophyGlucocorticoid-induced osteopaeniaOsteogenesis imperfectaZoledronic acid

More Related Videos

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

11.9K
Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model07:12

Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model

Published on: September 28, 2017

8.4K

Related Concept Videos

Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
4.8K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
106
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
128
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
102
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
89
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.5K